ChIPseq analysis of changes in binding of TFCP2L1 antibody in B16F0 cells in response to SX-682 treatment.

To define the activity of TFCP2L1 following CXCR2 perturbation, we performed chromatin immunoprecipitation and sequencing analysis (CHIPseq) on B16F0 tumorigenic melanoma cells following treatment with vehicle or SX-682. Overall design: ChIPseq data for mouse melanoma B16F0 cells treated with SX-682 or DMSO control, and DNA is pulled down with TFCP2L1 antibody or IgG isotope control.

为明确CXCR2（CXC趋化因子受体2）扰动后TFCP2L1（转录因子CP2样蛋白1）的功能活性，我们对经溶剂对照或SX-682处理的B16F0致瘤黑色素瘤细胞开展了染色质免疫沉淀测序（CHIP-seq）分析。
整体实验设计：针对经SX-682或二甲基亚砜（DMSO）对照处理的小鼠黑色素瘤B16F0细胞，分别使用TFCP2L1抗体或IgG同型对照抗体进行免疫沉淀，富集结合TFCP2L1的DNA片段，获取对应的CHIP-seq测序数据。